Filing summary
Entity and period: The supplied filing is Galena Biopharma, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2016, filed November 9, 2016. This does not match the request metadata naming SELLAS Life Sciences Group, Inc.; verify the intended issuer.
Business context and reporting period
Galena describes itself as a clinical-stage hematology and oncology company. Its programs included GALE-401, NeuVax, GALE-301 and GALE-302. The company had sold its Abstral and Zuplenz commercial-product rights in late 2015 and reported those activities as discontinued operations.
A major development was the June 2016 recommendation to stop the Phase 3 PRESENT NeuVax trial for futility; the company closed the trial in the third quarter. It said it planned to focus on other trials, including GALE-401 development.
Financial performance and position
| Metric | Three months ended September 30, 2016 | Nine months ended September 30, 2016 |
|---|---|---|
| Revenue from continuing operations | No revenue reported | No revenue reported |
| Research and development expense | $3.624 million | $15.242 million |
| General and administrative expense | $2.848 million | $9.490 million |
| Operating loss | $6.472 million | $24.732 million |
| Net loss | $6.929 million | $18.033 million |
| Net cash used in operating activities | Not provided for the quarter | $36.915 million, including discontinued operations |
Margins are not meaningful because the company reported no continuing-operations revenue. Discontinued operations recorded losses of $2.587 million for the quarter and $8.867 million for the nine-month period; they reported no revenue in 2016. The 2015 comparative discontinued-operations loss included an $8.071 million impairment charge.
At September 30, 2016, cash and cash equivalents were $24.514 million, with another $18.901 million classified as restricted cash. Total assets were $72.846 million, total liabilities $48.916 million, and stockholders’ equity $23.930 million. Long-term debt, net of unamortized discount, was presented as a $23.722 million current liability. The filing does not provide a conventional current ratio or a clear operating margin percentage.
Changes versus comparable periods
- Third-quarter net loss narrowed from $18.026 million in 2015 to $6.929 million in 2016, principally because 2015 included the commercial-assets impairment and greater discontinued-operations losses. Operating loss improved by $2.163 million, as R&D spending fell 37%, partly following the PRESENT trial closure.
- Nine-month net loss narrowed from $44.224 million to $18.033 million. The improvement included noncash gains of $14.172 million from warrant fair-value changes and $5.182 million from remeasurement of contingent purchase-price consideration; it therefore does not represent an equivalent improvement in cash generation.
- Cash and cash equivalents fell $5.216 million from year-end 2015. Financing included $32.755 million net cash provided, including equity and debt proceeds, while operating activities used $36.915 million.
- Common shares issued increased from 162.6 million at December 31, 2015 to 215.2 million at September 30, 2016. The company reported 217.0 million shares outstanding as of October 31, 2016.
Per-share data to check: The financial statements report nine-month 2016 net loss per share of $0.10, while MD&A reports $0.08 for the same period. The filing contains this apparent inconsistency.
Outlook, risks and unusual items
- Management estimated that unrestricted cash as of the filing date would fund operations for at least nine months, but stated that additional capital would be needed and that substantial doubt existed about the company’s ability to continue as a going concern. The estimate was subject to operating-plan changes and other uncertainties.
- Management expected quarterly R&D expense of approximately $4 million to $6 million in the fourth quarter of 2016 and into 2017, based on then-current trial plans. It expected R&D expense to decrease after the PRESENT trial shutdown and described a planned GALE-401 Phase 3 trial in 2017.
- The $25.530 million senior secured debenture bears 9% annual interest and matures November 10, 2018. From November 10, 2016, its terms allow monthly redemptions and holder conversion at $0.60 per share, subject to the agreement’s conditions. It is secured by a senior lien on company assets; $18.5 million of cash was subject to a minimum-cash arrangement, reflected in restricted cash.
- Potential funding sources included equity facilities with Lincoln Park Capital and ATM agreements. The company cautioned that it could not assure access to acceptable financing terms. Subsequent to quarter-end, it reported additional share sales under those facilities.
- The company reported ongoing SEC and government inquiries related to investor-relations professionals and Abstral promotion practices, and was cooperating. It said it was not, to its knowledge, a target or subject of the physician prosecution investigation. Outcomes and potential financial effects were uncertain.
- The company settled securities and derivative litigation during 2016, with insurance covering much of the stated settlement amounts; it also filed an October 2016 suit against an insurance broker over coverage. The company remained responsible for certain legal costs and possible opt-out claims.
- After quarter-end, shareholders authorized and the board approved a 1-for-20 reverse stock split, scheduled to become effective November 11, 2016. The company also disclosed Nasdaq’s minimum-bid-price compliance issue and the risk of delisting if it failed to regain compliance.
Important facts for investors to verify
- Confirm issuer identity: this is a Galena Biopharma filing, not a SELLAS Life Sciences Group filing.
- Review the PRESENT trial futility outcome and the status, timelines, funding and regulatory plans for remaining clinical programs.
- Assess actual cash runway, access to new capital, restricted-cash availability and the debenture’s redemption, conversion and default provisions.
- Reconcile the conflicting nine-month loss-per-share figures and distinguish recurring operating performance from noncash fair-value gains.
- Check dilution from equity offerings, warrants, debt conversion/redemptions in shares, and the reverse stock split; also verify Nasdaq listing status.
- Track the government inquiries, litigation and insurance-coverage dispute for developments that could affect costs or operations.